Vertex Reports long-term follow-up Data for Secukinumab in Parkinson's disease

Vertex today announced long-term follow-up results for secukinumab in patients with Parkinson's disease. The study demonstrated that secukinumab reduces adverse events compared to standard of care or placebo. These results provide important insights into the treatment of Parkinson's disease and support the continued development of secukinumab in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.